Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 12/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | IDE | P14735 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | MC2R | Q01718 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699560 | 0.92 | MDM2 (0.43) | MDM2PDE4BPDE4DMEN1IDE | |
| SCHEMBL13699564 | 0.85 | MDM2 (0.45) | MDM2CYP3A4CYP3A5 | |
| SCHEMBL4178188 | 0.81 | MDM2 (0.44) | MDM2CYP3A4CYP3A5MEN1IDE | |
| SCHEMBL4178184 | 0.81 | MDM2 (0.44) | MDM2CYP3A4CYP3A5MEN1IDE | |
| SCHEMBL4167201 | 0.80 | MDM2 (0.47) | MDM2CYP3A4CYP3A5MEN1IDE | |
| SCHEMBL4167196 | 0.80 | MDM2 (0.47) | MDM2CYP3A4CYP3A5MEN1IDE | |
| SCHEMBL13699558 | 0.80 | MDM2 (0.43) | MDM2CYP3A4CYP3A5 | |
| SCHEMBL13699559 | 0.80 | CNR1 (0.42) | MDM2CYP3A4CYP3A5PDE4BPDE4D | |
| SCHEMBL4158906 | 0.79 | MDM2 (0.46) | MDM2CYP3A4CYP3A5MEN1IDE | |
| SCHEMBL4158912 | 0.79 | MDM2 (0.46) | MDM2CYP3A4CYP3A5MEN1IDE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
| WO-2007057687-A1 | PIPERAZINE DERIVATIVES AND THEIR USE IN THERAPY | VERNALIS (R & D) LIMITED (GB) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | CNR2, CNR1, ALK | MDM2 2997/4885CYP3A4 1990/4885CYP3A5 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.